Oruka Therapeutics (ORKA)

Profile

Full Name

Oruka Therapeutics, Inc.

Ticker Symbol

ORKA

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

Indexes

Not included

Website

http://orukatx.com

Employees

28

Key Details

Price

$9.22(+7.08%)

Market cap

$345.20M(Small cap)

Last Dividend

$19.36

TTM Dividend yield

209.94%

Annual revenue

-

Annual EPS

-

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$9.22
ORKA price is $9.22

30-Day Relative Volume

0.44
ORKA 30-day relative volume is 0.44

Price Performance

Price Most recent change

+7.08%
ORKA price was up +7.08% on Apr 17, 2025

Price YTD change

-52.45%
ORKA price is down -52.45% since January 1st

Price 1-year change

-76.06%
ORKA price is down -76.06% year-on-year

Price 3-year change

-67.17%
ORKA price is down -67.17% over the past 3 years

Price Range

Price All-time high

$75932640.00
ORKA price is currently -100.00% below its historical high of $75932640.00

Price 3-year low

$5.49
ORKA price is currently +67.94% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$345.20M
ORKA market capitalization is $345.20 million

Market cap 3-year change

-
ORKA market capitalization 3-year change is unknown

Market cap All-time high

$1.07B
ORKA market capitalization is currently -67.65% below its historical high of $1.07 billion

Market cap sector rank

64.53%
ORKA market capitalization is higher than 64.53% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-
ORKA shares outstanding 1-year change is unknown

Shares Outstanding 3-Year Change

-
ORKA shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.09
ORKA beta is 1.09

200-day SMA

$22.99
ORKA price is currently -59.89% below its 200-day simple moving average

50-day SMA

$10.40
ORKA price is currently -11.31% below its 50-day simple moving average

RSI

47.67
ORKA 14-day relative strength index is 47.67

Volume

0.44
ORKA 30-day relative volume is 0.44

ATR

$0.92
ORKA average true range is $0.92

10-day Historical Volatility

111.79%
ORKA 10-day historical volatility is 111.79%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$19.36
ORKA last dividend was $19.36 per share, with an ex-dividend date of August 29, 2024

Next Dividend

-
ORKA next dividend has not yet been announced

Dividend per share

Dividend per share

$19.36
ORKA annual dividend per share is $19.36

Dividend per share Sector Rank

-
ORKA annual dividend per share is unknown

Dividend per share 1-Year Change

0%
ORKA {parameterFullLabel} has remained unchanged year-on-year

Dividend per share 3-Year Change

0%
ORKA {parameterFullLabel} has remained unchanged over the past 3 years

Dividend yield

Dividend yield

209.94%
ORKA annual dividend yield is 209.94%

Dividend yield Sector Rank

98.84%
ORKA annual dividend yield is higher than 98.84% of companies in Healthcare sector

Other

Payout ratio

-
ORKA annual payout ratio value is unknown

Dividends paid

-
ORKA annual dividends paid value is unknown

Free cash flow

-
ORKA annual free cash flow value is unknown

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
ORKA annual revenue value is unknown

Revenue Analysts estimate

-
ORKA annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
ORKA annual revenue 1-year change is unknown

Revenue Sector rank

-
ORKA annual revenue is unknown

EPS

EPS

-
ORKA annual earnings per share value is unknown

EPS Analysts estimate

-$2.40
ORKA annual earnings per share is currently equal to the consensus analysts' forecast

EPS 1-year change

-
ORKA annual earnings per share 1-year change is unknown

EPS Sector rank

-
ORKA annual earnings per share is unknown

Profit

Gross profit

-
ORKA annual gross profit value is unknown

Gross margin

-
ORKA annual gross profit margin value is unknown

Operating profit

-
ORKA annual operating income value is unknown

Operating margin

-
ORKA annual operating profit margin value is unknown

Net income

-
ORKA annual net profit value is unknown

Net margin

-
ORKA annual net profit margin value is unknown

Expenses

Total expenses

-
ORKA annual total expenses value is unknown

Operating expenses

-
ORKA annual total operating expenses value is unknown

Cost of goods sold

-
ORKA annual cost of goods sold value is unknown

Selling, general & administrative expenses

-
ORKA annual SGA value is unknown

Depreciation and amortization

-
ORKA annual depreciation & amortization value is unknown

Interest expense

-
ORKA annual interest expense value is unknown

Income tax

-
ORKA annual income tax value is unknown

EBIT & EBITDA

EBIT

-
ORKA annual earnings before interest & taxes value is unknown

EBITDA

-
ORKA annual EBITDA value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$396.02M
ORKA annual total assets is $396.02 million

Non current assets

$19.15M
ORKA annual long term assets is $19.15 million

Current assets

$376.87M
ORKA annual total current assets is $376.87 million

Cash and cash equivalents

$61.58M
ORKA annual cash & cash equivalents is $61.58 million

Accounts receivable

-
ORKA annual accounts receivable value is unknown

Inventory

-
ORKA annual inventory value is unknown

Liabilities

Total liabilities

$13.80M
ORKA annual total liabilities is $13.80 million

Long term liabilities

$755.00K
ORKA annual total long term liabilities is $755.00 thousand

Current liabilities

$13.04M
ORKA annual total current liabilities is $13.04 million

Accounts payable

$3.46M
ORKA annual accounts payable is $3.46 million

Debt

Total debt

$968.00K
ORKA annual total debt is $968.00 thousand

Total debt 1-year change

0%
ORKA {parameterFullLabel} has remained unchanged year-on-year

Long term debt

$755.00K
ORKA annual long term debt is $755.00 thousand

Short term debt

$213.00K
ORKA annual short term debt is $213.00 thousand

Equity & Capital

Shareholders equity

$382.22M
ORKA annual stockholders equity is $382.22 million

Book value

$379.29M
ORKA annual book value is $379.29 million

Retained earnings

-$83.72M
ORKA annual retained earnings is -$83.72 million

Working capital

$363.83M
ORKA annual working capital is $363.83 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-
ORKA annual cash flow from operations value is unknown

Cash from operations 1-year change

-
ORKA annual cash flow from operations 1-year change is unknown

Cash from investing

-
ORKA annual cash flow from investing activities value is unknown

Cash from investing 1-year change

-
ORKA annual cash flow from investing activities 1-year change is unknown

Cash from financing

-
ORKA annual cash flow from financing activities value is unknown

Cash from financing 1-year change

-
ORKA annual cash flow from financing activities 1-year change is unknown

CAPEX

CAPEX

-
ORKA annual capital expenditures value is unknown

CAPEX 1-year change

-
ORKA annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-
ORKA annual free cash flow value is unknown

Free cash flow 1-year change

-
ORKA annual free cash flow 1-year change is unknown

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
ORKA annual gross profit margin value is unknown

Operating margin

-
ORKA annual operating profit margin value is unknown

Net margin

-
ORKA annual net profit margin value is unknown

ROA & ROE

ROA

-
ORKA annual return on assets value is unknown

ROE

-
ORKA annual return on equity value is unknown

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
ORKA price to earnings ratio value is unknown

PE ratio Sector rank

-
ORKA price to earnings ratio is unknown

PB Ratio

PB ratio

1.02
ORKA price to book ratio is 1.02

PB ratio Sector rank

45.18%
ORKA price to book ratio is higher than 45.18% of companies in Healthcare sector

PS Ratio

PS ratio

-
ORKA price to sales ratio value is unknown

PS ratio Sector rank

-
ORKA price to sales ratio is unknown

Enterprise value

Enterprise value

-$64.69M
ORKA enterprise value is -$64.69 million

Enterprise value Sector rank

1.24%
ORKA enterprise value is higher than 1.24% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

1.30
ORKA EV/EBITDA is 1.30

EV/EBITDA Sector rank

75.2%
ORKA EV/EBITDA is higher than 75.2% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

28.89
ORKA annual current ratio is 28.89

Quick ratio

-
ORKA annual quick ratio value is unknown

Leverage

Debt to equity

0.00
ORKA annual debt to equity ratio is 0.00

Interest coverage ratio

-
ORKA annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
ORKA piotroski f-score value is unknown

Altman Z-Score

-
ORKA altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Feb 7, 25 HC Wainwright & Co.
Buy
Feb 4, 25 Wolfe Research
Outperform
Dec 20, 24 HC Wainwright & Co.
Buy
Nov 25, 24 HC Wainwright & Co.
Buy
Oct 31, 24 HC Wainwright & Co.
Buy
Oct 11, 24 Stifel
Buy
Oct 7, 24 HC Wainwright & Co.
Buy
Sep 17, 24 Leerink Swann
Outperform
Sep 17, 24 Leerink Partners
Outperform
Sep 16, 24 TD Cowen
Buy

Institutional Ownership

Similar stocks

PACB logo
Pacific Biosciences of California (PACB)
ALT logo
Altimmune (ALT)
NPCE logo
NeuroPace (NPCE)
ORIC logo
ORIC Pharmaceuticals (ORIC)
CKPT logo
Checkpoint Therapeutics (CKPT)
CLPT logo
ClearPoint Neuro (CLPT)
AMLX logo
Amylyx Pharmaceuticals (AMLX)
CYH logo
Community Health Systems (CYH)
NNOX logo
Nano-X Imaging (NNOX)
  • What is the ticker symbol for Oruka Therapeutics?
  • Does Oruka Therapeutics pay dividends?
  • What sector is Oruka Therapeutics in?
  • What industry is Oruka Therapeutics in?
  • What country is Oruka Therapeutics based in?
  • Is Oruka Therapeutics in the S&P 500?
  • Is Oruka Therapeutics in the NASDAQ 100?
  • Is Oruka Therapeutics in the Dow Jones?
  • When was Oruka Therapeutics's last earnings report?
  • When does Oruka Therapeutics report earnings?
  • Should I buy Oruka Therapeutics stock now?

What is the ticker symbol for Oruka Therapeutics?

The ticker symbol for Oruka Therapeutics is NASDAQ:ORKA

Does Oruka Therapeutics pay dividends?

Yes, Oruka Therapeutics pays dividends. The last payment was $19.36, with an ex-dividend date on August 29, 2024

What sector is Oruka Therapeutics in?

Oruka Therapeutics is in the Healthcare sector

What industry is Oruka Therapeutics in?

Oruka Therapeutics is in the Biotechnology industry

What country is Oruka Therapeutics based in?

Oruka Therapeutics is headquartered in United States

Is Oruka Therapeutics in the S&P 500?

No, Oruka Therapeutics is not included in the S&P 500 index

Is Oruka Therapeutics in the NASDAQ 100?

No, Oruka Therapeutics is not included in the NASDAQ 100 index

Is Oruka Therapeutics in the Dow Jones?

No, Oruka Therapeutics is not included in the Dow Jones index

When was Oruka Therapeutics's last earnings report?

Oruka Therapeutics's most recent earnings report was on Apr 15, 2025

When does Oruka Therapeutics report earnings?

The date for Oruka Therapeutics's next earnings report has not been announced yet

Should I buy Oruka Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page